Novartis China Announces Departure of Oncology Therapeutic Area Head Yan Qiong and Interim Leadership Appointment

Jul 17, 2024 16:14 CST Updated 16:14

Novartis China

Innovative Drug Developer

Pharmaceutical giant Novartis sees another personnel change. Yan Qiong, the current head of the oncology therapeutic area at Novartis China, is about to step down. This position will be temporarily filled by Chen Hui, the current head of retail, emerging markets, and the commercial department, who will report to the general manager.

The following is the full official announcement:

Dear colleagues:

Since the beginning of this year, our Oncology Division has continuously made breakthroughs and achieved outstanding results:

In terms of performance, overall achievements have been made. After Kaililong entered the medical insurance, the business grew rapidly; it also reaped a lot in the approval of new products and new indications. The successful approval of Tori, a new lung cancer drug, and Fida, a new drug in the hematology field, as well as the approval of Jakavi for chronic graft-versus-host disease indications, further expanded the innovative product line. The Haiyan radioligand therapy production base started construction in early July, which will provide innovative drugs required for precise tumor treatment to Chinese patients in the future. I sincerely thank all colleagues in the Oncology Business Unit. It is your relentless efforts and contributions that have achieved these remarkable results, and it is your hard work that brings hope to more cancer patients.

Announcement of Changes in the China Management Team of the International Business Department. Yan Qiong, the current head of the oncology treatment field, will leave Novartis due to external opportunities. We thank Yan Qiong for her work and contributions during her time at Novartis.

Effective August 1, 2024, Chen Hui, the current head of retail and commerce, will temporarily take on the role of head of oncology in addition to his current responsibilities, and will report to the General Manager.

Thanks to Chen Hui for taking on this responsibility during the transition period, and best wishes to Yan Qiong for future success and all the best.

The company is actively looking for a successor for this position and will keep everyone updated on the progress in a timely manner.

Yan Qiong once served as the head of Novartis' immunotherapy field. She has a diversified educational background with a bachelor's degree in biomedical engineering from Capital Medical University and a master's degree in computer artificial intelligence from the UK. She worked in AstraZeneca's oncology division for nine years before starting her career at Novartis in 2012.

On July 29, 2021, Novartis China underwent structural adjustments across multiple business units. Among these changes, the county-level team was transferred to the Immunology, Hepatology, and Dermatology Business Unit, and Yan Qiong, the then head of the Cardiovascular, Renal, and Metabolic Business Unit, was appointed as the head of the Immunology, Hepatology, and Dermatology Business Unit.

On June 1, 2022, the new organizational structure of Novartis Innovative Drugs China officially took effect, with Qiong Yan, former head of the Immunology Division of Novartis Pharmaceuticals China, assuming the role of Head of Immunotherapy at Novartis Innovative Drugs China. In October of the same year, Qiong Yan left Novartis to join Menarini as the Chief Executive Officer of Menarini China.

After Yan Qiong returned to Novartis, she focused on the market promotion of Novartis' key oncology product, Kayrilon (Ribociclib Succinate Tablets), as well as the growth of Jakavi and Tafinlar-Mekinist. Kayrilon is the first key product after the merger of Novartis Pharmaceuticals and Novartis Oncology. During Yan Qiong's tenure, overall performance was achieved, realizing rapid business growth and further expanding the innovative product pipeline.

Source: Siqi Club

Business Cooperation

130 6172 3098

zakk.cui@siqibest.com

ClickRead the Original Text Learn More